The Department of Health and Human Services yesterday released initial data on how states and territories plan to use their share of 100 million rapid point-of-care tests for the COVID-19 virus, which the agency began distributing last month.

The initial data includes 32 states and the District of Columbia. The Food and Drug Administration in August authorized laboratories certified to perform moderate, high or waived complexity tests under the Clinical Laboratory Improvement Amendment to use the Abbot BinaxNOW antigen test to detect SARS-CoV-2 in nasal swabs from individuals whose health care provider suspects they have COVID-19 within seven days of symptom onset.

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…